KEY DETAILS
A medRxiv preprint (Oct 21, 2026) reported comparable GI adverse events (23.3% vs 18.8%) with linafexor added to low-dose semaglutide.
A preprint looked at what happens when researchers added linafexor, a pulsatile FXR agonist, to low-dose semaglutide, the active ingredient in Wegovy and Ozempic. The findings have not yet gone through outside scientific review, so they describe one early study rather than a settled result. Here is what the preprint reported.
The preprint, posted to medRxiv with a last action date of October 21, 2026, is titled as examining linafexor, a pulsatile FXR agonist, added to low-dose semaglutide in adults with obesity, MASH, and type 2 diabetes. It reported that gastrointestinal adverse events were comparable, at 23.3% versus 18.8%. It also noted no treatment-related serious adverse events or discontinuations. This is a preprint, which means it has not been peer reviewed, so these figures reflect this one study as reported and have not been confirmed through outside review.
That is what the preprint entry reports for now. You can read the complete preprint on medRxiv for the details as reported.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.